In response to the government's call for proactive measures to address the rising burden of liver diseases in India, City Imaging & Clinical Labs has taken a significant step by launching FibroScan, an advanced diagnostic tool designed for rapid, painless, and non-invasive liver assessment.

This initiative aligns with the national focus on early detection and prevention, particularly in the context of non-alcoholic fatty liver disease (NAFLD), which is fast becoming a major health crisis in India.

Union Minister Dr Jitendra Singh, during the recent launch of the Indo-French Liver and Metabolic Disease Network (InFLiMeN), emphasised the growing prevalence of NAFLD in India.

“Every third Indian has fatty liver, which often predates Type 2 diabetes and other metabolic disorders,” said Dr. Singh, who himself is a nationally renowned diabetologist. He stressed the need for India-specific interventions to address this growing epidemic, given the country’s unique metabolic and genetic profile.

The launch of FibroScan at City Imaging’s Dwarka branch is a direct response to this call for action. With this the City Imaging has extended its reach also. The device provides a Controlled Attenuation Parameter (CAP) and liver stiffness assessment, making it an essential tool for the early detection of liver conditions such as NAFLD and alcoholic liver disease (ALD). These conditions, if left undiagnosed, can progress to serious complications like cirrhosis and liver cancer.

The FibroScan technology offers several key features, including its ability to deliver rapid results in just minutes. It is painless and non-invasive, eliminating the need for traditional biopsies or invasive procedures. Designed to be affordable, it ensures accessibility for a wide range of patients.